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To compare effectiveness of ACEis/ARBs for protecting DM2 patients from renal function decline in a real world setting.
Methods:
Retrospective cohort study of new ACEi/ARB users in 2007-2012 in an unselected primary care DM2 population. Outcome is decline in renal function stage (combining eGFR and albuminuria). Patients were matched on a propensity score. Extended Cox models with time-varying covariates were used to estimate hazard ratios of outcome.
Results:
The time to renal function decline for ARB users was slightly, but not significantly longer than for ACEi users (HR = 0.80, 95%CI [0.58-1.10], p=0.166).
Conclusion:
This study did not show significant differences between the classes in preventing renal function decline in DM2 patients in primary care.
Keywords: Angiotensin Converting Enzyme inhibitors; Angiotensin Receptor Blockers; Comparative effectiveness research; Primary care; Renal function decline; Type 2 diabetes; observational research; cohort study
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BACKGROUNDDiabetic patients with renal complications are at increased risk for cardiovascular events and, if untreated, of increased renal function decline [1,2]. Diabetic nephropathy occurs in 20–40% of all diabetic patients and has become the leading cause of end stage renal disease (ESRD) in the western world [1]. As the most clinically relevant pharmacological agents that block the renin-angiotensin-aldosterone system (RAAS), angiotensin converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) have been extensively 
studied in randomized controlled trials (RCTs) on their beneficial effects on cardiovascular morbidity and mortality across various populations. Although differences in modes of action between ACEis and ARBs introduce controversial discussion about effects on mortality or myocardial infarction risk [3-5], both ACEis and ARBs have been shown to be renoprotective in diabetic patients [6,7], and either of these drug classes are recommended 
as first choice treatment in diabetic patients with hypertension [1,8]. Head-to-head comparisons in RCTs (i.e. comparing an ACEi directly with an ARB) are relatively rare, 
and the findings in protective effects between the two classes are still inconclusive [9,10]. Recently, two network meta-analyses of antihypertensive treatment in diabetic patients on ESRD and on secondary kidney function outcomes from RCTs found that both ACEi and 
ARB monotherapy showed significant protective effects in preventing ESRD and doubling of serum creatinine, but comparison between ACEis and ARBs did not reach statistical 
significance [6,7]. RCTs may have the limitation, due to the patient selection criteria, that 




Outcome measures for renal function in studies comparing ACEis and ARBs include 
albuminuria, estimated glomerular filtration rate (eGFR), doubling of serum creatinine, occurrence of ESRD, or mortality. The use of this variety of indicators of renal function complicates comparison between studies. Instead of using a single biomarker, a functional 
classification into renal function stages has been developed [18], acknowledging that 
glomerular filtration rate and albumin secretion are independently associated with adverse outcomes. Several studies have used this measure of renal function stages to analyse kidney function in patients with diabetes or cardiovascular diseases [19,20], with the advantage 
of enabling the quantification of early onset renal function decline. To our knowledge 
no observational drug effectiveness studies have used this classification as an outcome measure.The objective of this study is to compare the effectiveness of ACEis and ARBs for protecting DM2 patients from renal function decline in a real world setting. In addition we will explore 
the effect modification of the initial renal function stage.
METHODS
Study designThis study is a retrospective, longitudinal cohort study in an unselected primary care population of about 35,000 patients with type 2 diabetes in the Northern Netherlands. Patients receiving diabetes care from their general practitioner (GP) between 2007 and 2012 were eligible for inclusion in the study.
Cohort definitionData from the GIANTT (Groningen Initiative to Analyse Type 2 diabetes Treatment) cohort are used. The GIANTT database contains anonymized data extracted from structured tables and free text parts of electronic medical records using an automated and validated method [21].We included patients who initiated treatment with ACEi or ARB between 2007 and 2012.
Initiation of ACEis or ARBs is defined as a prescription during the study period, without a prescription of any RAAS-inhibitors in the preceding 365 days. Apparent non-use in this period due to temporary absence from the general practice was manually checked with full 
patient data; false initiators due to temporary non-use were excluded. The date of this first 
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prescription is the index date. Within class switches during follow-up are allowed, since the different ACEis or ARBs drugs are considered to have similar effects [22].Exclusion criteria were: (1) treatment stopped within 6 months; (2) no baseline eGFR measurement (last 12 months before the index date); (3) no eGFR measurements after 
90 days of the index date, since the first 3 months of treatment were usually for changing therapies or titrating dose [23] so that eGFR measurements after 3 months were assumed 
to reflect effectiveness of a stable treatment regimen.
Patient characteristicsPatient characteristics used were demographic characteristics (age, gender, time since 
DM2 diagnosis), risk factor measurements (systolic/diastolic blood pressure (SBP/DBP), 
HbA1c, total cholesterol (TC), high/low density lipoprotein cholesterol (HDL-C/LDL-C), triglycerides (TG), renal function stage, body mass index (BMI) and smoking status). The last observed value of these characteristics during the year before the index date was used as baseline value, and all observations during follow-up were recorded. Baseline status of cardiovascular comorbidities (ischaemic heart disease with angina, acute myocardial 
infarction, ischaemic heart disease without angina, heart failure, atrial fibrillation, cardiac 
arrhythmia, stroke/cerebrovascular accident, cerebrovascular disease, atherosclerosis/
peripheral vascular disease) was defined as a diagnosis ever before index. The use of other antihypertensives (diuretics, calcium channel blockers, beta-blockers) during the year before index date was assessed to obtain baseline co-medication status, and the exposure to these drugs, as well as the ACEi or ARB during follow-up was recorded.
Outcome measureOutcome is renal function decline, as measured by the combination of eGFR and 
albuminuria-to-creatinine ratio (ACR) in five renal function stages [18] (Supplementary 
Table 1). Baseline renal function stage was determined by the last available eGFR and ACR 





Patients were followed from the index date until the first occurrence of: (1) reaching the 
outcome: confirmed renal function decline, defined by two consecutive stage observations worse than baseline; (2) moving out of the general practice; (3) death; (4) end of data availability.
Statistical analysis
Missing values of baseline characteristicsSince in the Netherlands diabetes management is highly protocolized with three-monthly visits resulting in standardized observations of the variables used in this study, we expect the missingness to be at random. Therefore we used multiple imputation to impute missing baseline values of albuminuria, SBP, DBP, HbA1c, TG, TC, HDL-C, LDL-C, BMI and smoking status. In our pre-analyses, 10 multiple imputed datasets were used as suggested in the literature [24]. Baseline and follow-up renal function stages were partly dependent on imputed baseline albuminuria values, causing different follow-up periods and outcomes between imputed datasets. Since there is no guidance on the number of imputations needed for a fair estimate of effects in such a situation, we conservatively chose a high number, 25. To improve computing performance, all further analyses were performed in each imputed dataset separately, after which the results were combined using Rubin’s rules [25] and pooled results are reported.
Propensity score matchingTo minimize confounding by indication [26], patients starting on ACEi and ARB treatment were matched on a propensity score (PS), using all available baseline characteristics. ACEi users were matched with ARB users at a ratio of 1:1 using a nearest neighbour matching algorithm with a maximum caliper. The post-matching C-statistic [27], a multivariate statistic to assess balance on all covariates simultaneously, was used to identify the caliper at which the number of matched patients decreased faster than the achieved balance. 
A caliper of 0.01 was identified as optimal. To assess imbalance in individual baseline characteristics, the standardized mean difference (SDD) was calculated [28].
Survival AnalysisThe time to renal function decline was analysed using an extended Cox model with time-varying covariates in the propensity score matched cohort. The time-varying covariates were SBP, DBP, BMI, HbA1c, TG, cardiovascular comorbidities, as well as study and co-
medication (expressed in units of Defined Daily Dose (DDD) per day [29]).
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Patients can leave the cohort due to moving house (for example to a nursing home, or another region) or death. Since these reasons can be related to the study outcome, competing risks models treating moving or death as competing risks, were used instead of 
a standard Cox model, to calculate hazard ratios (HRs) of confirmed renal function decline. Models incorporating the interaction between renal function stage and drug treatment 
were used to explore effect modification by the initial renal function stage on ACEi/ARB effectiveness.Data preparation and statistical analyses were performed using Stata MP Version 12.0 (Stata Corporation, College Station, TX).
Ethics StatementFor research using anonymous medical records no ethics committee approval is needed in The Netherlands. The study protocol was approved by the GIANTT Steering Group.
RESULTSAfter applying the inclusion and exclusion criteria, 3,633 patients were selected for the analyses. Among them, 2,830 patients were taking ACEis and 803 patients were taking 
ARBs (the types of ACEis/ARBs received by the study participants were showed in 




Figure 1. Patient selection flow of study.ACEi: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; eGFR: 
Estimated glomerular filtration rate.In the unmatched population the C-statistic of exposure was 0.606, indicating some relevant differences of baseline characteristics for treatment choice. The worst balanced 
characteristics were the use of CCB and β-blocker medication, gender, short DM2 duration, SBP, BMI availability and HbA1c with SDDs ranging from 0.194 to 0.102 (Table 1). The pooled post-matching C-statistic of 0.544 in the 25 imputed cohorts indicated good balance between the treatment groups. All baseline characteristics had a pooled SDD below 0.1, which means the matching resulted in well-balanced baseline values between the treatment groups.
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Table 1. Baseline characteristics before and after propensity score matching.
Before matching After matching*
ACEi
N (%) / Mean 
(SD)
ARB















Before matching After matching*
ACEi
N (%) / Mean 
(SD)
ARB










SDDIschaemic heart disease with angina 197 (7.0%) 56 (7.0%) 0.000 6.4% 6.8% 0.027Acute myocardial infarction 207 (7.3%) 59 (7.4%) 0.001 6.9% 7.0% 0.024Ischaemic heart disease without angina 229 (8.1%) 65 (8.1%) 0.000 7.6% 7.7% 0.025Heart failure 103 (3.6%) 34 (4.2%) 0.031 4.0% 4.0% 0.018
Atrial fibrillation 118 (4.2%) 47 (5.9%) 0.077 5.4% 5.2% 0.023Cardiac arrhythmia 70 (2.5%) 18 (2.2%) 0.015 1.7% 1.9% 0.025
Stroke/cerebrovascular accident 91 (3.2%) 25 (3.1%) 0.006 3.1% 3.1% 0.019Cerebrovascular disease 31 (1.1%) 9 (1.1%) 0.002 1.1% 1.1% 0.025
Atherosclerosis/peripheral vascular disease 177 (6.3%) 41 (5.1%) 0.050 4.8% 5.0% 0.021Co-medicationDiuretics 967 (34.2%) 300 (37.4%) 0.067 37.8% 37.2% 0.020Calcium channel blocker 338 (11.9%) 152 (18.9%) 0.194 19.2% 18.0% 0.030
β-blocker 966 (34.1%) 342 (42.6%) 0.175 43.6% 42.1% 0.031C-statistic of logistic model for PS 0.606 0.544* Pooled means of value or percentage and their pooled SDD from 25 imputed datasets.† Pooled mean of number of matched patients (standard deviation) from 25 imputed datasets.ACEi: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; DBP: Diastolic blood pressure; DM2: Type 2 diabetes mellitus; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; PS: Propensity score; SBP: Systolic blood pressure; SD: Standard deviation; SDD: Standardized mean difference.
The follow-up periods were similar in the ACEi and ARB groups (2,287 and 2,280 person-years respectively), with a pooled average follow-up time of 2.9 years in both groups (Table 
2). The average drug exposure over the follow-up period, presented as the average DDD, 
was significantly higher in the ARB than in the ACEi users (1.12 vs. 1.07 DDD/day; p=0.001). This was not caused by a difference in adherence, since the medication possession ratio 
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(MPR) was similar (ACEi: 85.0%, ARB: 83.9%; p=0.175). The median number of renal stage measurements per year was similar in both groups (1.6, p=0.205).
Table 2. Comparison of follow-up periods in matched sample (25 imputed datasets).
Pooled mean / median Pooled
P-valueACEi ARBNumber of renal stage measurement during follow-up per year (median) 1.6 1.6 0.205*Total follow-up time, person-years (mean) 2,286.6 2,279.7Total follow-up time, years (mean) 2.9 2.9 0.727*
Average drug exposure over the follow-up period (DDD/day) (mean) 1.07 1.12 0.001*Medication possession ratio (MPR) (mean) 85.0 % 83.9 % 0.175
Number of patients with confirmed renal function decline (outcome) (median) 119 99 0.186*** Rank sum test** Log-rank test
ACEi: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; DDD: Defined daily dose; MPR: Medication possession ratio.
The pooled average number of outcomes (deterioration of renal function stage) was 217 (13.9%) in the 25 imputed cohorts. The average numbers of occurred competing risk events of moving and death were 31 (2.0%) and 27 (1.8%), respectively. The competing risk regression model favoured ARBs over ACEi (pooled adjusted HR=0.80, 95%CI [0.58-
1.10]) to protect against renal function decline but the effect is not statistically significant (p=0.166). Among the 25 analyses in the imputed datasets the p-value ranged from 0.010 to 0.917, with 8 having a value below 0.05 (table in Supplementary Table 3). We did not 




DISCUSSIONThis study compared effectiveness of ACEis and ARBs for protection against renal function decline in patients with type 2 diabetes in a real world setting. We used an PS matching method based on multiple imputed datasets. Survival models with competing risks showed that ACEis and ARBs were similar in protecting DM2 patients from renal function decline (HR=0.80, 95%CI [0.58-1.10], p=0.166), although the effect slightly favoured ARBs.These results are in line with the majority of head-to-head comparisons between ACEi and ARB [30-37] in diabetic patients, and also in hypertensive patients [38] with some exceptions that favoured one over another [17,39,40]. Our study differs in several aspects from earlier studies. The main differences are the outcome and the population included. Our study focussed on the process of renal decline based on both GFR and albuminuria irrespective of the initial renal function. Therefore, our results apply to patients with 
different baseline renal function stages. In earlier studies the outcome was defined as 
either GFR/creatinine or albuminuria, or end stage disease outcome, e.g. ESRD, or all-cause mortality.In addition, the follow-up in most earlier RCTs [30-34,39] is often relatively short (from 24 weeks to 1 year), and limited to one follow-up measurement. The negative results in 
these studies must be interpreted with caution because therapy duration may significantly 
influence the ability to detect meaningful changes in renal function.Our study used longitudinal time-to-event follow-up that may strengthen the statistical power to detect differences in effectiveness between ACEis and ARBs. The three observational studies with direct comparison used the same time to event follow-up data [17,37,40], but only one included adequate adjustment for confounding by indication [17]. However that study included a selected population with macroalbuminuria and showed ACEis to be more effective.Another difference from other studies is the unselected population included, with patients ranging from renal function stage one to four, i.e. from normal renal function to severe renal function dysfunction. Therefore our results may be generalizable to the general diabetic 
population. We found no effect modification of the baseline renal stage. In the earlier 
studies the population was usually limited to patients with specific renal dysfunction. For instance, the majority of RCTs included patients with microalbuminuria [30-34] and the ONTARGET trial only included patients with end-organ damage [36].
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Strength of our study is the use of observational data of an unselected population of patients with DM2 as registered during the regular care process. Through the PS matching we succeeded in reducing the measured confounding. Besides well-balanced baseline characteristics our analysis adjusted for time-varying characteristics as well.The study also has some limitations. The number of events in the matched population was relatively small, resulting in limited power to differentiate between the effectiveness of ACEi and ARB. Secondly, in studies based on data obtained during regular care missing data are a potential problem [41]. Although we used multiple imputation, our assumption that missingness was random could have been wrong. However, analysis using complete cases showed essentially the same results (Supplementary Table 3).
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Supplementary Table 1. Classification of renal function based on both eGFR* and ACR*
ACR (mg/mmol)stage Normoalbuminuria Microalbuminuria MacroalbuminuriaM: ACR<2.5F: ACR<3.5 M: 2.5≤ACR<25F: 3.5≤ACR<35 M: 25≤ACR<167F: 35≤ACR<233 M: ACR≥167F: ACR≥233eGFR
 (ml/min per 1.73 m2)
S1 eGFR≥90 Stage 1 Stage 2 Stage 3 Stage 5S2 60≤eGFR<90S3A 45≤eGFR<60 Stage 2 Stage 3 Stage 4 Stage 5S3B 30≤eGFR<45 Stage 3 Stage 4 Stage 4 Stage 5S4 15≤eGFR<30 Stage 4 Stage 4 Stage 4 Stage 5S5 eGFR<15 Stage 5 Stage 5 Stage 5 Stage 5
* eGFR = estimated glomerular filtration rate; ACR = albuminuria-to-creatinine ratio.


























































































































































































































































































































































































































































































































































































































































































Supplementary Figure 1. Adjusted HRs with 95% confidence interval for imputed cases (blue) and complete cases (red), by imputation dataset.
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